Bieżący numer
Archiwum
Online first
O czasopiśmie
Redakcja
Rada Naukowa
Wydawca
Standardy etyczne i procedury
Bazy indeksacyjne
Recenzenci
Recenzenci Honorowi
Prenumerata
Kontakt
Najczęściej czytane artykuły
Dla autorów
Opłata za przetwarzanie artykułu (APC)
Książki i Konferencje
Książki
Konferencje
SARS CoV-2/COVID-19
PRACA ORYGINALNA
The relationship between the presence of autoantibodies, indicators of systemic and local inflammation, the serum concentration of B-cell activating factor and the intensity of salivary gland infiltration in patients with primary Sjögren’s syndrome – a preliminary study.
Data nadesłania: 31-12-2015
Data ostatniej rewizji: 19-01-2016
Data akceptacji: 19-01-2016
Data publikacji online: 11-02-2016
Data publikacji: 15-02-2016
Reumatologia 2015;53(6):321-327
SŁOWA KLUCZOWE
DZIEDZINY
STRESZCZENIE
Objectives: The aim of this study was to find markers related to activation of B cells, which show a correlation with the systemic inflammation markers – erythrocyte sedimentation rate and C-reactive protein and with the intensity of in situ inflammation.
Material and methods: Forty-one primary Sjögren’s syndrome (pSS) patients (33 female, 8 male) of the mean age 52.9 ±15 years were included. A group of 20 healthy volunteers was applied as a control. Erythrocyte sedimentation rate (ESR), concentration of gamma-globulins, C-reactive protein (CRP) and rheumatoid factor (RF) were measured by routine laboratory tests. Titres of antinuclear antibodies (ANAs) were determined by the indirect immunofluorescence method, while anti-SS-A/SS-B antibodies were detected by both the dot-blot method and an enzyme immunoassay. The concentrations of BAFF in sera were measured by sandwich ELISA. Biopsies of minor salivary glands were taken and the focus score (FS) was calculated. Correlations between quantitative variables were assessed using the Spearman correlation coefficient (r).
Results: Serum concentrations of BAFF was significantly higher in the pSS patients than in the control group. The study revealed a statistically significant correlation between ANAs titre and the FS (r = 0.421).
Anti-SS-A/Ro and anti-SS-B/La antibodies positively correlated with ESR. There was also a positive correlation between the gamma globulin level and the titres of all tested autoantibodies.
Conclusions: The positive correlation between ANAs and FS confirms the importance of these autoantibodies in the local inflammatory process. The positive correlation between anti-SS-A/SS-B antibodies and ESR suggests involvement of these antibodies in generalization of the inflammatory response. In the pSS group serum concentrations of BAFF were statistically significantly higher than healthy volunteers. All presented results confirm the role of activity of B cells in the course of pSS.
Material and methods: Forty-one primary Sjögren’s syndrome (pSS) patients (33 female, 8 male) of the mean age 52.9 ±15 years were included. A group of 20 healthy volunteers was applied as a control. Erythrocyte sedimentation rate (ESR), concentration of gamma-globulins, C-reactive protein (CRP) and rheumatoid factor (RF) were measured by routine laboratory tests. Titres of antinuclear antibodies (ANAs) were determined by the indirect immunofluorescence method, while anti-SS-A/SS-B antibodies were detected by both the dot-blot method and an enzyme immunoassay. The concentrations of BAFF in sera were measured by sandwich ELISA. Biopsies of minor salivary glands were taken and the focus score (FS) was calculated. Correlations between quantitative variables were assessed using the Spearman correlation coefficient (r).
Results: Serum concentrations of BAFF was significantly higher in the pSS patients than in the control group. The study revealed a statistically significant correlation between ANAs titre and the FS (r = 0.421).
Anti-SS-A/Ro and anti-SS-B/La antibodies positively correlated with ESR. There was also a positive correlation between the gamma globulin level and the titres of all tested autoantibodies.
Conclusions: The positive correlation between ANAs and FS confirms the importance of these autoantibodies in the local inflammatory process. The positive correlation between anti-SS-A/SS-B antibodies and ESR suggests involvement of these antibodies in generalization of the inflammatory response. In the pSS group serum concentrations of BAFF were statistically significantly higher than healthy volunteers. All presented results confirm the role of activity of B cells in the course of pSS.
REFERENCJE (30)
1.
Alamanos Y, Tsifetaki N, Voulgari PV, et al. Epidemiology of primary Sjögren’s syndrome in north-west Greece, 1982–2003. Rheumatol Oxf Engl 2006; 45: 187-191.
2.
Patel R, Shahane A. The epidemiology of Sjögren’s syndrome. Clin Epidemiol 2014; 6: 247-255.
3.
Kallenberg CGM, Vissink A, Frans GM, et al. What have we learned from clinical trials in primary Sjögren’s syndrome about pathogenesis? Arthritis Res Ther 2011; 13: 205.
4.
Maślińska M, Przygodzka M, Kwiatkowska B, Sikorska-Siudek K. Sjögren’s syndrome: still not fully understood disease. Rheumatol Int 2015; 35: 233-241.
5.
Igoe A, Scofield RH. Autoimmunity and infection in Sjögren’s syndrome. Curr Opin Rheumatol 2013; 25: 480-487.
6.
Radić M. Role of Helicobacter pylori infection in autoimmune systemic rheumatic diseases. World J Gastroenterol 2014; 20: 12839-12846.
7.
Fabris M, Dolcetti R, Pasini E, et al. High prevalence of Chlamydophila psittaci subclinical infection in Italian patients with Sjögren’s syndrome and parotid gland marginal zone B-cell lymphoma of MALT-type. Clin Exp Rheumatol 2014; 32: 61-65.
8.
Johnson EO, Skopouli FN, Moutsopoulos HM. Neuroendocrine manifestations in Sjögren’s syndrome. Rheum Dis Clin North Am 2000; 26: 927-949.
9.
Tzioufas AG, Tsonis J, Moutsopoulos HM. Neuroendocrine dysfunction in Sjogren’s syndrome. Neuroimmunomodulation 2008; 15: 37-45.
10.
Tincani A, Andreoli L, Cavazzana I, et al. Novel aspects of Sjögren’s syndrome in 2012. BMC Medicine 2013; 11: 93.
11.
Groom J, Kalled SL, Cutler AH, et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren’s syndrome. J Clin Invest 2002; 109: 59-68.
12.
Aqrawi LA, Skarstein K, Bredholt G, et al. Autoantigen-specific memory B cells in primary Sjögren’s syndrome. Scand J Immunol 2012; 75: 61-68.
13.
Varin MM, Guerrier T, Devauchelle-Pensec V, et al. In Sjögren’s syndrome, B lymphocytes induce epithelial cells of salivary glands into apoptosis through protein kinase C delta activation. Autoimmun Res 2012; 11: 252-258.
14.
Smoleńska Ż, Bilińska M, Kujawska-Danecka H, Zdrojewski Z. Obwodowy układ nerwowy w pierwotnym zespole Sjögrena. Reumatologia 2013; 51: 202-209.
15.
Shiboski SC, Shiboski CH, Criswell L, et al. American College of Rheumatology classification criteria for Sjögren’s syndrome: a data-driven, expert consensus approach in the Sjögren’s International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken) 2012; 64: 475-487.
16.
Rasmussen A, Ice JA, Li H, et al. Comparison of the American-European Consensus Group Sjogren’s syndrome classification criteria to newly proposed American College of Rheumatology criteria in a large, carefully characterised sicca cohort. Ann Rheum Dis 2014; 73: 31-38.
17.
Rose-Nussbaumer J, Lietman TM, Shiboski CH, et al. Sjögren’s International Collaborative Clinical Alliance Research Groups. Inter-grader Agreement of the Ocular Staining Score in the Sjögren’s International Clinical Collaborative Alliance (SICCA) Registry. Am J Ophthalmol 2015; 160: 1150-1153.e3.
18.
Whitcher JP, Shiboski CH, Shiboski SC, et al. Sjögren’s International Collaborative Clinical Alliance Research Groups. A simplified quantitative method for assessing keratoconjunctivitis sicca from the Sjögren’s Syndrome International Registry. Am J Ophthalmol 2010; 149: 405-415.
19.
Sotoa ME, Hernández-Becerrila N, Perez-Chineya AC, et al. Predictive value of antinuclear antibodies in autoimmune diseases classified by clinical criteria: Analytical study in a specialized health institute, one year follow-up. Res Immunol 2015; 5: 13-22.
20.
Theander E, Jonsson R, Sjöström B, et al. Prediction of Sjögren’s Syndrome Years Before Diagnosis and Identification of Patients With Early Onset and Severe Disease Course by Autoantibody Profiling. Arthritis Rheum 2015; 67: 2427-2436.
21.
Yoshimi R, Ueda A, Ozato K, Ishigatsubo Y. Clinical and pathological roles of Ro/SSA autoantibody system. Clin Dev Immunol 2012; 2012: 606195.
22.
Hamza N, Bos NA, Cees GM. Kallenberg CG. B-cell populations and sub-populations in Sjögren’s syndrome. Presse Méd 2012; 41: 475-483.
23.
Huang Y, Cheng Q, Jiang Ch, et al. The Immune Factors Involved in the Pathogenesis, Diagnosis and Treatment of Sjogren’s Syndrome. Clin Dev Immunol 2013; 2013: 160491.
24.
Mariette X, Roux S, Zhang J, et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren’s syndrome. Ann Rheum Dis 2003; 62: 168-171.
25.
Mumcu G, Biçakçigil M, Yilmaz N, et al. Salivary and serum B-cell activating factor (BAFF) levels after hydroxychloroquine treatment in primary Sjögren’s syndrome. Oral Health Prev Dent 2013; 11: 229-234.
26.
Ittah M, Miceli-Richard C, Gottenberg EJ, et al. B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren’s syndrome. Arthritis Res Ther 2006; 8: R51.
27.
Daridon C, Devauchelle V, Hutin P, et al. Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjögren’s syndrome. Arthritis Rheum 2007; 56: 1134-1144.
28.
Harrison M. Erythrocyte sedimentation rate and C-reactive protein. Aust Presc 2015; 38: 93-94.
29.
Enocsson H, Sjöwall C, Skogh T, et al. Interferon-alpha mediates suppression of C-reactive protein: explanation for muted C-reactive protein response in lupus flares? Arthritis Rheum 2009; 60: 3755-3760.
30.
Yaoa Y, Liua Z, Jallala B, et al. Type I interferons in Sjögren’s syndrome. Autoimmun Rev 2013; 12: 558-566.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Udostępnij
ARTYKUŁ POWIĄZANY
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
Przetwarzamy dane osobowe zbierane podczas odwiedzania serwisu. Realizacja funkcji pozyskiwania informacji o użytkownikach i ich zachowaniu odbywa się poprzez dobrowolnie wprowadzone w formularzach informacje oraz zapisywanie w urządzeniach końcowych plików cookies (tzw. ciasteczka). Dane, w tym pliki cookies, wykorzystywane są w celu realizacji usług, zapewnienia wygodnego korzystania ze strony oraz w celu monitorowania ruchu zgodnie z Polityką prywatności. Dane są także zbierane i przetwarzane przez narzędzie Google Analytics (więcej).
Możesz zmienić ustawienia cookies w swojej przeglądarce. Ograniczenie stosowania plików cookies w konfiguracji przeglądarki może wpłynąć na niektóre funkcjonalności dostępne na stronie.
Możesz zmienić ustawienia cookies w swojej przeglądarce. Ograniczenie stosowania plików cookies w konfiguracji przeglądarki może wpłynąć na niektóre funkcjonalności dostępne na stronie.
